Although there is no clear evidence towards Ki67 prognostic value, a statement made by Chargari in 2007 seems to remain a reasonable approach, which is to take into consideration the value of proliferation index Ki67 as well as the presence of mass of the tumour in MR imaging, diameter of the primary tumour (higher progression risk in tumours > 4 cm) or cystic structure of the tumour while making the decision on the use of radiotherapy as adjuvant therapy [45]⁠. Here, MKI67 is linked to neoplasm.